These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22300068)

  • 1. Adherence with migraine prophylaxis in clinical practice.
    Berger A; Bloudek LM; Varon SF; Oster G
    Pain Pract; 2012 Sep; 12(7):541-9. PubMed ID: 22300068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and determinants of migraine prophylactic medication in the Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beliefs about medicines and adherence among Swedish migraineurs.
    Hedenrud T; Jonsson P; Linde M
    Ann Pharmacother; 2008 Jan; 42(1):39-45. PubMed ID: 18073328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological basis of migraine prophylaxis.
    Galletti F; Cupini LM; Corbelli I; Calabresi P; Sarchielli P
    Prog Neurobiol; 2009 Oct; 89(2):176-92. PubMed ID: 19654035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to oral migraine-preventive medications among patients with chronic migraine.
    Hepp Z; Dodick DW; Varon SF; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2015 May; 35(6):478-88. PubMed ID: 25164920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of migraine preventive medications among patients with and without migraine headaches.
    Lafata JE; Tunceli O; Cerghet M; Sharma KP; Lipton RB
    Cephalalgia; 2010 Jan; 30(1):97-104. PubMed ID: 19489877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of disease features on adherence to prophylactic migraine medication.
    Linde M; Jonsson P; Hedenrud T
    Acta Neurol Scand; 2008 Dec; 118(6):367-72. PubMed ID: 18513346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive treatment of migraine.
    Silberstein SD
    Rev Neurol Dis; 2005; 2(4):167-75. PubMed ID: 16622394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.
    Oladapo AO; Barner JC; Rascati KL; Strassels SA
    Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Migraine-related vertigo: diagnostic criteria and prophylactic treatment.
    Maione A
    Laryngoscope; 2006 Oct; 116(10):1782-6. PubMed ID: 17003732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight change associated with the use of migraine-preventive medications.
    Taylor FR
    Clin Ther; 2008 Jun; 30(6):1069-80. PubMed ID: 18640463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
    Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK
    Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701
    [No Abstract]   [Full Text] [Related]  

  • 15. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current trends in migraine prophylaxis.
    Ramadan NM
    Headache; 2007 Apr; 47 Suppl 1():S52-7. PubMed ID: 17425710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' preference for migraine preventive therapy.
    Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
    Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older.
    Patterson ME; Blalock SJ; Smith AJ; Murray MD
    Clin Ther; 2011 May; 33(5):608-16. PubMed ID: 21665045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prophylactic treatments of migraine].
    Massiou H
    Rev Neurol (Paris); 2000; 156 Suppl 4():4S79-86. PubMed ID: 11139754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug prophylaxis for migraine headaches.
    Walling AD
    Am Fam Physician; 1990 Aug; 42(2):425-32. PubMed ID: 1974381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.